Table 6.

Incidence of all-grade gastrointestinal adverse events in cancer patients treated with ICI [66, 71, 74–76, 78, 92]

Drugs/irAE	Anti-PD-1/PD-L1	Anti-CTLA-4	Combined treatment
Diarrhea	0.7–19.1% [74] 14.1–18.2% [78] 19.2% [66]	25–50% [92] 27–54% [71] 27.5–41.2% [74] 29.2% [78] 33.1% [66]	16.3–45.0% [74] 26.1–40.5% [78] 44.1% [66]
Colitis	0.3–19.1% [74] 1–5% [75] 1.3% [66] 1.8–2.1% [78] 2.2% [71]	7.6–15.5% [74] 8.0% [78] 8–22% [71] 10–25% [75] 11.6% [66]	1–13% [74] 9.2–13.4% [78] 11.8% [66] 12.8% [71] 20% [75]
Hepatitis	0.3–10.8% [74] 0.9–3.0% [78] 1–2% [71] 1.1–7.6% [76] 3.8% [75]	0.4% [78] 1.2–4.3% [76] 3–19% [71] 3.4–10.8% [74] 3.9% [75]	3.5–33% [74] 4.9–9.8% [78] 17.6% [75] 25–30% [66] 27.7% [76]